SXTP and SXTPW Related Headlines
Go Back- 60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial
- 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
- 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
- 60 Degrees Pharma makes malaria drug available on telehealth platform
- 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
- 60 Degrees Pharmaceuticals Announces 2025 Annual Results
- 60 Degrees Pharmaceuticals files FDA notification for dietary supplement
- 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
- 60 Degrees Pharmaceuticals reports babesiosis cures in small trial
- 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
- 60 Degrees Pharmaceuticals partners with GoodRx for ARAKODA discounts
- 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
- 60 Degrees Pharmaceuticals exercises license option for castanospermine
- 60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
- 60 Degrees Pharmaceuticals partners with Runway Health for malaria drug
- 60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
- 60 Degrees Pharmaceuticals to implement 1-for-4 reverse stock split
- 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
- 60 Degrees Pharmaceuticals finds Babesia in 24% of chronic fatigue patients
- 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
- 60 Degrees Pharmaceuticals plans ARAKODA sales expansion for 2026
- 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
- 60 Degrees Pharmaceuticals opens site for chronic babesiosis study
- 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
- 60 Degrees Pharmaceuticals reports first patient clears babesia infection
- 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
- 60 Degrees Pharmaceuticals names chronic babesiosis trial B-FREE
- 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
- Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
- 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
- 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
- 60 Degrees Pharmaceuticals picks Mount Sinai for babesiosis trial
- 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
- 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
- 60 Degrees Pharmaceuticals partners with Tulane to study lyme treatment
- 60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
- 60 Degrees Pharmaceuticals closes $5 million public offering
- 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering
- 60 Degrees Pharmaceuticals prices $5 million public offering
- 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
- 60 Degrees Pharmaceuticals estimates $245M annual market for babesiosis drug
- 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
- 60 Degrees Pharmaceuticals plans FDA submission for canine babesiosis drug
- 60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
- 60 Degrees Pharmaceuticals (SXTP) Expands Options for Malaria Prevention with Introduction of ARAKODA 8-Count Bottle Format
- 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
SXTP and SXTPW Related Press Releases
Go Back- 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
- 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
- 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
- 60 Degrees Pharmaceuticals Announces 2025 Annual Results
- 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
- 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
- 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
- 60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
- 60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
- 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
- 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
- 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
- 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
- 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
- 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
- Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
- 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
- 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
- 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
- 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
- 60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
- 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering
- 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
- 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
- 60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
- 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
